[1]冯变莹,陈静奇,郝湘文,等.竹节参皂苷IVa调控DNMT1表达影响肝细胞癌细胞株增殖、迁移、侵袭及干性特征研究[J].现代检验医学杂志,2026,41(05):46-51.[doi:10.3969/j.issn.1671-7414.2026.05.008]
　FENG Bianying,CHEN Jingqi,HAO Xiangwen,et al.The Research of Chikusetsusaponin IVa Regulated DNMT1 Expression toAffect Proliferation, Migration, Invasion, and Stemness of Hepatocellular Carcinoma Cells[J].Journal of Modern Laboratory Medicine,2026,41(05):46-51.[doi:10.3969/j.issn.1671-7414.2026.05.008]
点击复制

竹节参皂苷IVa调控DNMT1表达影响肝细胞癌细胞株增殖、迁移、侵袭及干性特征研究()

《现代检验医学杂志》[ISSN:/CN:]

卷:
第41卷
期数:
2026年05期
页码:
46-51
栏目:
论著
出版日期:
2026-09-15

文章信息/Info

Title:
The Research of Chikusetsusaponin IVa Regulated DNMT1 Expression toAffect Proliferation, Migration, Invasion, and Stemness of Hepatocellular Carcinoma Cells
文章编号:
1671-7414 （2026） 05-046-06
作者:
冯变莹，陈静奇，郝湘文，宗鸣，陈皓，满秋红
（同济大学附属上海市第四人民医院检验科，上海200434）
Author(s):
FENG Bianying, CHEN Jingqi, HAO Xiangwen, ZONG Ming, CHEN Hao, MAN Qiuhong
(Department of Labo- ratory Medicine, Shanghai Fourth People’s Hospital Affiliated to Tongji University, Shanghai 200434, China)
关键词:
竹节参皂苷IVa;  肝细胞癌;  DNA甲基转移酶1;  增殖;  迁移;  侵袭;  干性特征
分类号:
R735.7； R730.4
DOI:
10.3969/j.issn.1671-7414.2026.05.008
文献标志码:
A
摘要:
目的 探究竹节参皂苷IVa （CsIVa） 调控肝细胞癌细胞生长、 转移及干细胞特性的功能及机制。 方法 qRT-PCR和 Western blot检测DNA甲基转移酶1 （DNMT1） mRNA和蛋白在肝细胞癌细胞株HepG2、 Huh7、 Hep3B、 MHCC97-H和人肝 细胞LO2中的表达。HepG2细胞分为CsIVa 0、 50、 100、 200 μmol/L组和CsIVa 200 μmol/L+ DNMT1组。CCK-8、 流式细 胞术和细胞成球实验检测各组细胞增殖、 凋亡和干性， Transwell法检测细胞迁移和侵袭能力。Western blot检测各组细胞 干性标志物 （Nanog、 Sox2、 Oct4、 KLF4和CD133） 蛋白表达。 结果 MHCC97-H、 Hep3B、 Huh7和HepG2中DNMT1 mRNA 和蛋白表达水平均显著高于其在LO2中的DNMT1 mRNA和蛋白表达 （tmRNA=8.10~45.09， t蛋白=4.63~22.66， 均P＜0.05） 。 与CsIVa 0 μmol/L组比较， CsIVa 50、 100和200 μmol/L组HepG2细胞DNMT1表达、 细胞增殖、 迁移、 侵袭、 细胞成球 数显著降低， 差异具有统计学意义 （t=4.32~36.18， 均P＜0.05） ， Nanog、 Sox2、 Oct4、 KLF4和CD133蛋白表达显著降低， 差异具有统计学意义 （t=4.09~39.27， 均P＜0.05） ， 细胞凋亡率显著增加 （t=7.12~18.34， 均P＜0.05） 。 与CsIVa 200 μmol/L 组比较， CsIVa 200 μmol/L+ DNMT1组HepG2细胞DNMT1表达、 细胞增殖、 迁移、 侵袭、 细胞成球数显著增加， 差异具 有统计学意义 （t=7.42~16.35， 均P＜0.05） ， Nanog、 Sox2、 Oct4、 KLF4和CD133蛋白表达显著增加， 差异具有统计学意义 （t=10.79~24.80， 均P＜0.05） ， 细胞凋亡显著降低 （t=4.48， P＜0.05） 。 结论 CsIVa下调DNMT1表达而抑制肝细胞癌细胞生 长和转移能力以及干细胞特性。
Abstract:
Objective To explore the function and mechanism of chikusetsusaponin IVa (CsIVa) in regulating the growth, metas- tasis, and stemness characteristics of hepatocellular carcinoma cells. Methods qRT-PCR and Western blot were used to detect the mRNA and protein expression of DNA Methyltransferase 1(DNMT1) in hepatocellular carcinoma cell lines HepG2, Huh7, Hep3B, and MHCC97-H, as well as in human hepatocytes LO2. HepG2 cells were divided into groups treated with 0, 50, 100, or 200 μmol/L CsIVa, and a group treated with 200 μmol/L CsIVa + DNMT1 overexpression. CCK-8 assay, ?ow cytometry, and cell spheroid formation assay were used to assess cell proliferation, apoptosis, and stemness characteristics, respectively. Transwell assay was used to evaluate cell migration and invasion abilities. Western blot was used to detect the protein expression of stemness markers (Nanog, Sox2, Oct4, KLF4, and CD133) in each group of cells. Results The expression levels of DNMT1 mRNA and protein in MHCC97-H, Hep3B, Huh7, and HepG2 were signi?cantly higher than those in LO2 (tmRNA= 8.10~45.09, tprotein= 4.63~22.66, all P < 0.05). Compared with the CsIVa 0 μmol/L group, the CsIVa 50, 100, and 200 μmol/L groups showed signi?cantly reduced DNMT1 expression, cell proliferation, migration, invasion, and cell spheroid formation in HepG2 cells (t=4.32~36.18, all P < 0.05), the protein levels of Nanog, Sox2, Oct4, KLF4, and CD133 were also signi?cantly decreased (t=4.09~39.27, all P<0.05), and the apoptosis rate was signi?cantly increased (t=7.12~18.34, all P<0.05). Compared with the CsIVa 200 μmol/L group, the CsIVa 200 μmol/L + DNMT1 group showed signi?cantly increased DNMT1 expression, cell proliferation, migration, invasion, and cell spheroid formation in HepG2 cells (t=7.42~16.35, all P<0.05), the protein levels of Nanog, Sox2, Oct4, KLF4, and CD133 were also signi?cantly increased (t=10.79~24.80, all P< 0.05), and the apoptosis rate was signi?cantly reduced (t=4.48, P<0.05). Conclusions CsIVa downregulates DNMT1 expression to inhibit the growth, and meta- static potential, and stemness characteristics of hepatocellular carcinoma cells.

参考文献/References:

[1] 张乔盟,杨蕊菲,冯飞雪,等.原发性肝细胞癌相关风 险评估模型的最新研究进展[J].现代检验医学杂志, 2025, 40(1): 203-207. ZHANG Q M, YANG R F, FENG F X, et al. Latest research progress on risk scoring models for primary hepatocellular carcinoma[J]. Journal of Modern Labo- ratory Medicine, 2025, 40(1): 203-207.
[2] RIZZO A, BRUNETTI O, BRANDI G. Hepatocellular carcinoma immunotherapy: predictors of response, is- sues, and challenges[J]. International Journal of Molec- ular Sciences, 2024, 25(20): 11091.
[3] COUZINET A, SUZUKI T, NAKATSURA T. Progress and challenges in glypican-3 targeting for hepatocellu- lar carcinoma therapy[J]. Expert Opinion on Therapeu- tic Targets, 2024, 28(10): 895-909.
[4] SATO-ESPINOZA K, VALDIVIA-HERRERA M, CHOTIPRASIDHI P, et al. Hepatocellular carcinoma in patients without cirrhosis[J]. World Journal of Gastro- enterology, 2025, 31(23): 107100.
[5] BLOOM M, PODDER S, DANG H, et al. Advances in immunotherapy in hepatocellular carcinoma[J]. Interna- tional Journal of Molecular Sciences, 2025, 26(5): 1936.
[6] YEO Y H, ABDELMALEK M, KHAN S, et al. Current and emerging strategies for the prevention of hepatocel- lular carcinoma[J]. Nature Reviews Gastroenterology & Hepatology, 2025, 22(3): 173-190.
[7] LIU Y W, LUO R Y, LIU A Q, et al. Identi?cation of chikusetsusaponin IVa as a novel lysine-specific de- methylase 1 inhibitor that ameliorates high fat diet-in- duced MASLD in mice[J]. Acta Pharmacologica Sinica, 2025, 46(3): 632-652.
[8] YANG Y S, JIANG Y F, QIAN D Y, et al. Chikusetsusa- ponin IVa improves osseointegration by inhibiting osteo- blast ferroptosis via the GSK3β/NRF2/GPX4 pathway[J]. Biochemical Pharmacology, 2025, 242(Pt 1): 117227.
[9] LIANG Y T, FAN T T, BAI M, et al. Chikusetsu Sapo- nin IVa liposomes modi?ed with a retro-enantio peptide penetrating the blood-brain barrier to suppress pyropto- sis in acute ischemic stroke rats[J]. Journal of Nanobio- technology, 2024, 22(1): 393.
[10] XIE Q, LIU Y, LONG Y, et al. Hybrid-cell membrane-coat- ed nanocomplex-loaded chikusetsusaponin IVa methyl ester for a combinational therapy against breast cancer assisted by Ce6[J]. Biomater Sci, 2021, 9(8): 2991-3004.
[11] SONG X M, WANG W, ZHANG X, et al. Deglucose chi- kusetsusaponin IVa isolated from Rhizoma Panacis Majo- ris induces apoptosis in human HepG2 hepatoma cells[J]. Molecular Medicine Reports, 2015, 12(4): 5494-5500.
[12] T?TH D M, SZERI F, ASHABER M, et al. Tissue-spe- ci?c roles of de novo DNA methyltransferases[J]. Epi- genetics & Chromatin, 2025, 18(1): 5.
[13] LI J W, CHENG X Z, HUANG D G, et al. Six2 reg- ulates the malignant progression and 5-FU resistance of hepatocellular carcinoma through the PI3K/AKT/ mTOR pathway and DNMT1/E-cadherin methylation mechanism[J]. Neoplasma, 2024, 71(5): 451-462.
[14] HA N B, YAO F. Alcohol and hepatocellular carcinoma[J]. Clinics in Liver Disease, 2024, 28(4): 633-646.
[15] ZHONG B Y, FAN W Z, GUAN J J, et al. Combination locoregional and systemic therapies in hepatocellular carcinoma[J]. Lancet Gastroenterology Hepatology, 2025, 10(4): 369-386.
[16] SHA M, LI X H, LIU Y, et al. Comparative chemical characters of Pseudostellaria heterophylla from geo- graphical origins of China[J]. Chinese Herbal Medi- cines, 2023, 15(3): 439-446.
[17] YANG Y, WEN L, JIANG Z Z, et al. Chemical prop- erties,preparation, and pharmaceutical effects of cyclic peptides from Pseudostellaria heterophylla[J]. Mole- cules, 2025, 30(12): 2521-2540.
[18] GUI Y, WU H, FAN H. Pseudostellaria heterophylla (Miq.) Pax, a traditional folk medicine, ameliorates colorectal can- cer by remodeling the tumor immune microenvironment [J]. Journal of Ethnopharmacology, 2025, 342: 119362.
[19] PU Y W, ZHU J M, XU J, et al. Antitumor effect of a polysaccharide from Pseudostellaria heterophylla through reversing tumor-associated macrophages phe- notype[J]. International Journal of Biological Macro- molecules, 2022, 220: 816-826.
[20] LI H, WANG S Y, YANG Z S, et al. Advances in Pseu- dostellaria heterophylla research: current status and future directions[J]. Molecules, 2025, 30(17): 3656.
[21] ZHOU L Y, HE L Y, LIU C H, et al. Liver cancer stem cell dissemination and metastasis: uncovering the role of NRCAM in hepatocellular carcinoma[J]. Journal of Ex- perimental & Clinical Cancer Research, 2023, 42(1): 311.
[22] CHEN J S, ZHANG H X, XIU C Y, et al. METTL3 promotes pancreatic cancer proliferation and stemness by increasing stability of ID2 mRNA in a m6A-depen- dent manner[J]. Cancer Letters, 2023, 565: 216222.
[23] YAN L, GENG Q, CAO Z W, et al. Insights into DNMT1 and programmed cell death in diseases[J]. Biomedicine & Pharmacotherapy, 2023, 168: 115753.
[24] QIN S K, CHEN H H, TIAN C C, et al. NS1-mediat- ed DNMT1 degradation regulates human bocavirus 1 replication and RNA processing[J]. PLOS Pathogens, 2024, 20(11): e1012682.
[25] ZHU B, CHEN J J, FENG Y, et al. DNMT1-induced miR-378a-3p silencing promotes angiogenesis via the NF-κB signaling pathway by targeting TRAF1 in he- patocellular carcinoma[J]. Journal of Experimental & Clinical Cancer Research, 2021, 40(1): 352.
[26] CHEN M K, FANG Y, LIANG M N, et al. The activa- tion of mTOR signalling modulates DNA methylation by enhancing DNMT1 translation in hepatocellular carcinoma[J]. Journal of Translational Medicine, 2023, 21(1): 276.
[27] LI K J, NING T, WANG H, et al. Nanosecond pulsed electric ?elds enhance mesenchymal stem cells differ- entiation via DNMT1-regulated OCT4/NANOG gene expression[J]. Stem Cell Research & Therapy, 2020, 11(1): 308.
[28] YU Y, LU X H, YAN Y, et al. The lncRNA KIF9-AS1 accelerates hepatocellular carcinoma growth by recruit- ing DNMT1 to promote RAI2 DNA methylation[J]. Journal of Oncology, 2022, 2022: 3888798.

相似文献/References:

[1]杨文丽,申 旺,黄秀芳,等.磷脂酰肌醇蛋白聚糖3在肝细胞癌组织中的表达及临床意义[J].现代检验医学杂志,2016,31(01):73.[doi:10.3969/j.issn.1671-7414.2016.01.021]
　YANG Wen-li,SHEN Wang,HUANG Xiu-fang,et al.Expression and Clinical Significance of Glypican-3 in Hepatocellular Carcinoma Tissues[J].Journal of Modern Laboratory Medicine,2016,31(05):73.[doi:10.3969/j.issn.1671-7414.2016.01.021]
[2]张巧娣,谢而付,凌 芸,等.壳多糖酶3样蛋白1与甲胎蛋白在肝细胞癌诊断中的比较[J].现代检验医学杂志,2017,32(01):45.[doi:10.3969/j.issn.1671-7414.2017.01.013]
　ZHANG Qiao-di,XIE Er-fu,LING Yun,et al.Comparative Diagnostic Value of Chitinase 3-Like 1 Protein and AFP in the Diagnosis of Hepatocellular Carcinoma[J].Journal of Modern Laboratory Medicine,2017,32(05):45.[doi:10.3969/j.issn.1671-7414.2017.01.013]

备注/Memo

备注/Memo:
基金项目：上海市第四人民医院科研启动专项（sykyqd02201）。
作者简介：冯变莹（1985-），女，硕士研究生，主管技师，研究方向：细胞蛋白组学标志物筛选，E-mail：fengbianying@outlook.com。
更新日期/Last Update: 2026-09-15